By Scemblix at 50% discount from Insulinhub - European source.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine.
There are 2 manufacturing sites for Europe for Scemblix:
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Information about Scemblix (Asciminib)
Scemblix (Asciminib) is an oral medication used primarily in the treatment of chronic myeloid leukemia (CML), specifically for patients with Philadelphia chromosome-positive (Ph+) CML. Asciminib works by inhibiting the BCR-ABL1 tyrosine kinase, a protein that plays a key role in the development of CML. Scemblix is classified as a tyrosine kinase inhibitor (TKI) and offers a novel mechanism of action, distinct from other existing TKIs.
Product Highlights
- Chronic Myeloid Leukemia (CML) in the chronic phase (CP) with Philadelphia chromosome-positive (Ph+) CML.
- Patients who have resistant or intolerant to prior therapies, including other tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib.
Key Ingredient
Key Benefits
- Scemblix offers a more targeted approach to treatment by selectively inhibiting BCR-ABL1 kinase activity in CML.
- The drug acts through a different binding site (myristoyl pocket) than other TKIs, potentially reducing off-target effects.
- Scemblix has shown efficacy in patients who have become resistant or intolerant to other TKIs, offering a treatment option where other therapies have failed.
- Scemblix is administered orally, making it a convenient option for patients compared to intravenous therapies.
Direction of Use
- Scemblix is taken orally in tablet form, typically once a day.
- The dosage and specific instructions depend on the patient’s medical history, response to previous therapies, and any potential side effects. A healthcare provider will determine the appropriate dose.
- It should be taken at the same time every day, with or without food.
Safety Concerns
- The most common side effects of Scemblix include nausea, diarrhea, fatigue, headache, and abdominal pain. Serious side effects may include low blood cell counts, liver toxicity, or cardiovascular issues.
- Some patients may experience an increased risk of heart-related issues, such as arrhythmias.
- Monitoring liver function during treatment is important, as liver damage can occur.
Avoid Scemblix (Asciminib) If
- Scemblix is not recommended for use during pregnancy or while breastfeeding due to potential harm to the fetus or infant.
- Avoid Scemblix in patients with severe hepatic impairment, as the drug is metabolized by the liver and could exacerbate liver damage.
- Individuals who are allergic to Asciminib or any of the excipients in Scemblix should not use this medication.
- Scemblix may interact with certain medications, including strong CYP3A4 inducers and inhibitors, so it should be used cautiously when combined with other drugs.
